Scholarlink

Purpose of Review <p>To describe the incidence, prevention and treatment of heart failure with preserved ejection fraction (HFpEF) among patients with cancer.</p> Recent Findings <p>Many cancer therapeutics can predispose to HFpEF, including anthracyclines, radiation, hematopoietic stem cell transplant, vascular endothelial growth factor inhibitors, proteasome inhibitors, BCR-Abl inhibitors, anti-androgen therapy, immune checkpoint inhibitors. HFpEF has been understudied in cancer patients in part because definitions of cancer therapy related cardiac dysfunction have required a decrease in left ventricular ejection fraction. Sodium-glucose cotransporter 2 inhibitors are being studied for the prevention of cancer therapeutic related cardiac dysfunction and may be useful for the prevention of HFpEF in the setting of cancer treatment.</p> Summary <p> Management of HFpEF among cancer survivors combines existing treatment paradigms for non-cancer patients with a nuanced understanding of the increased cardiovascular risk secondary to cancer and cancer therapy. Future research should clearly define HFpEF as an outcome. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Heart Failure with Preserved Ejection Fraction among Cancer Patients

  • 期刊论文

  • 发表日期：

    2025年12月24日

查看全文
  • Jenica Upshaw,
  • Sophia Golec

摘要

Purpose of Review

To describe the incidence, prevention and treatment of heart failure with preserved ejection fraction (HFpEF) among patients with cancer.

Recent Findings

Many cancer therapeutics can predispose to HFpEF, including anthracyclines, radiation, hematopoietic stem cell transplant, vascular endothelial growth factor inhibitors, proteasome inhibitors, BCR-Abl inhibitors, anti-androgen therapy, immune checkpoint inhibitors. HFpEF has been understudied in cancer patients in part because definitions of cancer therapy related cardiac dysfunction have required a decrease in left ventricular ejection fraction. Sodium-glucose cotransporter 2 inhibitors are being studied for the prevention of cancer therapeutic related cardiac dysfunction and may be useful for the prevention of HFpEF in the setting of cancer treatment.

Summary

Management of HFpEF among cancer survivors combines existing treatment paradigms for non-cancer patients with a nuanced understanding of the increased cardiovascular risk secondary to cancer and cancer therapy. Future research should clearly define HFpEF as an outcome.